Ashwani Verma
Stock Analyst at UBS
Total Price Targets
30
Stocks Covered
15
Sectors
Healthcare
Most Recent
Apr 17, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Ashwani Verma
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc. | $19.00 | $12.84 | +48.0% | 1 | Apr 17, 2026 |
| CYTK | Cytokinetics, Incorporated | $69.00 | $64.40 | +7.1% | 2 | Mar 6, 2026 |
| VTRS | Viatris Inc. | $18.00 | $14.98 | +20.1% | 3 | Feb 9, 2026 |
| RPRX | Royalty Pharma plc | $49.00 | $49.41 | -0.8% | 3 | Jan 30, 2026 |
| ACAD | ACADIA Pharmaceuticals Inc. | $40.00 | $21.95 | +82.2% | 5 | Jan 6, 2026 |
| NBIX | Neurocrine Biosciences, Inc. | $188.00 | $131.64 | +42.8% | 4 | Jan 5, 2026 |
| CORT | Corcept Therapeutics Incorporated | $95.00 | $51.08 | +86.0% | 1 | Dec 16, 2025 |
| JAZZ | Jazz Pharmaceuticals plc | $188.00 | $202.38 | -7.1% | 2 | Nov 24, 2025 |
| EXEL | Exelixis, Inc. | $43.00 | $43.81 | -1.8% | 2 | Jul 11, 2025 |
| ALKS | Alkermes plc | $42.00 | $33.49 | +25.4% | 1 | Jun 17, 2025 |
| CHRS | Coherus Oncology, Inc. | $1.05 | $1.79 | -41.3% | 2 | Apr 24, 2025 |
| BIIB | Biogen Inc. | $202.00 | $186.69 | +8.2% | 1 | Oct 3, 2024 |
| HRMY | Harmony Biosciences Holdings, Inc. | $56.00 | $31.74 | +76.4% | 1 | Sep 10, 2024 |
| UTHR | United Therapeutics Corporation | $370.00 | $571.24 | -35.2% | 1 | Jul 8, 2024 |
| AXSM | Axsome Therapeutics, Inc. | $25.00 | $204.09 | -87.8% | 1 | Aug 10, 2021 |
Recent Activity
- Apr 17, 2026— Set$19.00price target onAMRX(Amneal Pharmaceuticals, Inc.)
- Mar 6, 2026— Set$69.00price target onCYTK(Cytokinetics, Incorporated)
- Feb 9, 2026— Set$18.00price target onVTRS(Viatris Inc.)
- Jan 30, 2026— Set$49.00price target onRPRX(Royalty Pharma plc)
- Jan 6, 2026— Set$40.00price target onACAD(ACADIA Pharmaceuticals Inc.)
- Jan 5, 2026— Set$188.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Dec 16, 2025— Set$95.00price target onCORT(Corcept Therapeutics Incorporated)
- Dec 4, 2025— Set$35.00price target onACAD(ACADIA Pharmaceuticals Inc.)
- Dec 1, 2025— Set$61.00price target onCYTK(Cytokinetics, Incorporated)
- Nov 24, 2025— Set$188.00price target onJAZZ(Jazz Pharmaceuticals plc)
- Oct 9, 2025— Set$195.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Aug 8, 2025— Set$36.00price target onACAD(ACADIA Pharmaceuticals Inc.)
- Jul 11, 2025— Set$43.00price target onEXEL(Exelixis, Inc.)
- Jun 17, 2025— Set$42.00price target onALKS(Alkermes plc)
- Apr 24, 2025— Set$1.05price target onCHRS(Coherus Oncology, Inc.)
- Jan 8, 2025— Set$162.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 3, 2024— Set$202.00price target onBIIB(Biogen Inc.)
- Sep 19, 2024— Set$30.00price target onEXEL(Exelixis, Inc.)
- Sep 10, 2024— Set$56.00price target onHRMY(Harmony Biosciences Holdings, Inc.)
- Jul 8, 2024— Set$370.00price target onUTHR(United Therapeutics Corporation)
Frequently Asked Questions
Who is Ashwani Verma?
Ashwani Verma is a stock analyst at UBS covering 15 stocks primarily in Healthcare. They have issued 30 price targets since Aug 10, 2021.
What stocks does Ashwani Verma cover?
Ashwani Verma currently covers 15 stocks, including ACAD, NBIX, VTRS, RPRX, CYTK.
What is Ashwani Verma's latest price target?
Ashwani Verma's most recent price target was $19.00 on AMRX (Amneal Pharmaceuticals, Inc.), set on Apr 17, 2026.
What is Ashwani Verma's highest price target?
Ashwani Verma's highest issued price target is $370.00 on UTHR, set on Jul 8, 2024.
More Analysts at UBS
Coverage based on publicly published price targets. Not investment advice.